Method of resort therapy of benign prostatic hyperplasia complicated by chronic prostatitis with dominant symptom of nocturia

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to urology and balneotherapy, and can be used for treating patients with benign prostatic hyperplasia complicated by chronic prostatitis with a dominant symptom of nocturia. That is ensured by performing EHF therapy. The above is combined with an integrated resort treatment: oral administration of carbonate-hydrocarbonate-sulphate sodium-calcium low-mineralised (3.6-3.7 g/l) water in an amount of 280-300 ml three times a day 40-45 minutes before meals. The balneological treatment is prescribed: taking baths with similar mineral water at a temperature of 36-37°C with the exposure of each procedure 15 minutes in the number of 8 procedures every second day. Phytomicroenemas are prescribed in the number of 8 procedures every second day. That is combined with drug therapy with artesine 2 mg/day for 10 days.

EFFECT: method enables the rehabilitation treatment which provides higher adaptation capabilities of the body, reducing the symptoms of the lower urinary tract with the dominant symptom of nocturia from 4-5 to 1-2 urinations a night and improving the quality of life in the patients undergoing the resort therapy It is manifested by the positive improvement of the patients' status as shown by the clinical examination, as well as by IPSS, Q max values.

3 tbl, 3 ex

 

The invention relates to medicine, namely to the section of internal diseases, and for improving the effectiveness of rehabilitation treatment of patients with benign prostatic hyperplasia, complicated by chronic prostatitis dominant symptom of nocturia, at the resort.

Significance of the problem

Benign prostatic hyperplasia (BPH) is one of the most frequent diseases in men, ranging from 40-50 years. Epidemiological studies indicate a trend of increasing life expectancy. Currently, the estimated life expectancy of men in Europe and North America is 72 years. The growth dynamics is such that between 1980 and 2050, the population aged over 65 years is projected to double and reach 15% of the entire human population. Thus, almost every man upon reaching a certain age will have histologically detectable hyperplasia of the prostate, and most importantly, 50% of them will have symptoms of lower urinary tract" (alyayev Y., et al. 2005).

Hyperplasia of the prostate is not only a serious health, but also a great social problem. Progressive nature of the flow, a gradual worsening of symptoms of lower urinary tract" lead the frequent complications, and, most importantly, negatively affect the quality of life of patients (Lopatkin N.A., 1999). In this regard, there is no doubt the importance of early detection of clinically significant forms of prostatic hyperplasia and timely appointment of adequate treatment. Although, in General, unambiguous understanding of the etiology and pathogenesis hyperplasia currently, there can be considered established several important points, the knowledge of which will allow an informed and reasonable to assign therapy of patients with benign prostatic hyperplasia.

Age and normal secretion of androgens are two of the most recognized factors in the development of benign prostatic hyperplasia. During the metabolism of testosterone penetrates into the cells of the prostate gland, where under the action of the enzyme 5A-reductase converts into dihydrotestosterone - the latter is the active androgen stimulating proliferation of cells in the prostate.

Also in the mechanism of development of benign prostatic hyperplasia in recent years, considerable allocating roles of estrogen. It is established that aging men strengthens the processes of peripheral aromatization of testosterone, which leads to a relative increase of estradiol in the blood plasma. I believe that it is NGOs estrogens leading to increased activity of 5A-reductase in prostate tissue during the development of hyperplasia. An excess of DHT causes hyperproduction collagen, muscle fibers and slow apoptosis (Mamaev, I. E., Shumylo D. C. 2007). The main clinical manifestations of benign prostatic hyperplasia are the symptoms of lower urinary tract (SNMP). Men of the fourth decade of life with symptoms of lower urinary tract occur in about 3.5% of cases, while in patients older than 70 years of clinical manifestations of benign prostatic hyperplasia occur in 35% of cases. Symptoms of lower urinary tract significantly degrade the quality of life of patients. Several studies have shown that severe symptoms of lower urinary tract stronger concern to patients than serious diseases such as hypertension, diabetes, angina and other Increases in life expectancy and the ageing of the population leads to the fact that doctors are increasingly turning patients with symptomatic benign prostatic hyperplasia. Advanced age, severe comorbidities require effective and safe treatment, relieving symptoms and improving quality of life.

However, from 20 to 30% of patients are not satisfied with the results of the treatment, do not celebrate reduce symptoms violation mosaicus is occurring and to improve the quality of life. In recent years it has become apparent that despite the benign nature prostatic hyperplasia is a progressive disease. The progression is manifested in the strengthening of disorders of urination, worsening quality of life, increasing the risk of acute urinary retention (AUR) and the need for surgery. Natural course of benign prostatic hyperplasia can be traced in large population studies and placebo groups double-blind randomized studies. One of them is the Olmsted county study population study, for 12 years watching 2115 men 40-79 years. In the beginning of the study, 26% of men aged 40-49 years had moderate and symptoms of the lower urinary tract. Aged 70-79 years, the prevalence of symptoms of lower urinary tract was 46%. During the observation it was noted signs of progress of the disease was aggravated by the severity of the symptoms of lower urinary tract, increased prostate cancer, has deteriorated urodynamic parameters. The average annual increase in the severity of symptoms on a scale IPSS (international scale evaluation of prostatic symptoms) was 0.18 points/year prostate volume was increased on average by 1.9%, peak urine flow rate (Qmax) at an average annual rate decreased by 2.1%. Total vstrechaemost the acute retention of urine within 4 years was 2.7%. Only 3% of men were operated on for benign prostatic hyperplasia.

The study MTOPS (Medical therapy of prostatic symptoms) became the first double-blind randomized placebo-controlled study investigated the effect of drug therapy on the progression of benign prostatic hyperplasia. Clinical disease progression was defined as an increase in the total number of points on a scale IPSS≥4, the occurrence of acute urinary retention, acute renal failure associated with benign prostatic hyperplasia, recurrent urinary tract infections, urinary incontinence. In the placebo group during 5 years of follow-up clinical disease progression was observed in 16.6% of patients. The most common manifestation of progression (79,5%) was subjective worsening of symptoms of lower urinary tract (increase IPSS≥4). Acute urinary retention occurred in 2% of patients in the placebo group, surgery for benign prostatic hyperplasia performed in 5%. Over 5 years of follow-up in the group not treated, the volume of the prostate increased by 24%, PSA levels increased by 14%.

These studies have made evident the fact that benign prostatic hyperplasia (BPH W is Lesa progresses in the absence of therapy, and detection of patients with high risk of disease progression is crucial in optimising their treatment (Joseph C. Presti, Jr., 2007).

The relevance of inventions

Symptoms of lower urinary tract (SNMP)caused by benign prostatic hyperplasia (BPH), complicated by chronic prostatitis (CP) is most often found in men with this pathology. These symptoms significantly affect daily activity and significantly impair quality of life. Nocturia significantly impairs sleep, leading to fatigue in the daytime, which in turn causes adverse changes in the condition of adaptation and does not permit a full sanatorium-resort rehabilitation of patients.

There is a method of treatment of benign prostatic hyperplasia in combination with chronic prostatitis, including magnetotherapy, laser therapy, transurethral electrical stimulation, neurostimulation and the color and rhythm therapy apparatus of the "Andro-Gin". In this way using a transurethral catheter with fiber conducting laser irradiation and stimulation of the prostate, which is an invasive procedure and limits the possibilities of its application. The additional impact of spend emitting nozzle with a semiconductor infrared laser diodes that it reduces the efficiency because of the remoteness from the prostate gland. The location of the sources of the red and infrared radiation scattered reduces the potentiation effect. The use of multiple magnetic heads (transrectal with a capacity of 15 MT and outer - 40 MT) complicates the procedure.

Also known is a method of treatment of benign prostatic hyperplasia, complicated by chronic prostatitis using miniconference laser therapeutic apparatus "MILTA-f" [1]. When this emitter is applied consistently in the crotch, over the pubis, groin and the area of the sacrum for 2 min, frequency 80 Hz, the radiated power of 50 mW, magnetic induction 20-80 MT, daily, in the course of 8-10 treatments.

The disadvantages of this method are:

1. Conducting magnetic impact with the surface of the body that removes from the pathological focus and reduces its effectiveness.

2. The complexity of the recipe conduct consisting in the sequential exposure to different areas that lengthens and complicates the treatment process.

3. Application of the apparatus "MILTA" requires compliance with all rules for working with laser equipment.

The closest in technical essence of the present invention is a method for "EHF-therapy in patients with benign prostatic hyperplasia and its combination with hroni the definition prostatitis" (Dunaevsky, Y. L., Semenov HP, Putilov, M. A.: "Andrology and genital surgery", 2002. No. 1. - S. 63-65).

This method causes beneficial changes in the state of adaptation. Reduces clinical manifestations of the disease. However, this method is not effective when expressed manifestations of symptoms of lower urinary tract, in particular nocturia. The main goal of treatment of patients at the resort with symptoms of lower urinary tract caused by benign prostatic hyperplasia, complicated by chronic prostatitis, should be relieved of the patient, and therefore is extremely important to become adequately prescribed treatment, leading to rapid improvement of symptoms and quality of life of the patient. Therefore requires a comprehensive multi-component approach to the rehabilitation of this category of patients, including EHF-therapy, drinking mineral water, balneotherapy, dosed physical activity and medication, including acceptance selective competitive blocker postsynaptic alpha-adrenergic receptors of artesina (international name: doxazosin (Doxazosin) in a daily dose of 2 mg. It will greatly improve adaptation period, symptoms, quality of life of the patient and the effectiveness of treatment in General. Data of scientific observations and practical work is s doctors sanatorium-resort establishments in this method is not available.

The technical result of the proposed method is to increase the adaptive capacities of the organism, reducing symptoms of the lower urinary tract with the dominant symptom of nocturia from 4-5 to 1-2 urination at night and improve the quality of life of patients in sanatorium-resort treatment.

This technical result is achieved by the fact that the applied method of treatment, including EHF-therapy, wherein the patient spend additional complex Spa treatment: internal reception to the carbon dioxide-bicarbonate-sulfate sodium-calcium water of low salinity - 3,6-3,7 g/l, in the amount of 280-300 ml, three times a day for 40-45 minutes prior to a meal, balneological treatment: bath with the similar mineral water, the temperature of 36-37°C with an exposure time of each procedure 15 minutes of 8 procedures for the course, through the day; photomicroscopy of 8 procedures for the course, through the day; and daily prescribed medication by artesina 2 mg/day for 10 days.

The proposed method of treatment was performed as follows: patients on a background of gentle or gently-training regimen physical activity, therapeutic feeding on diet No. 6, was appointed EHF-therapy was additionally appointed internal reception to the carbon dioxide-bicarbonate-sulfate sodium-calcium water of low salinity - 3,6-3,7 g/l, in which Alceste 3-5 ml per kilogram of body weight three times a day for 40-45 minutes prior to a meal, balneological treatment: bath with the similar mineral water, the temperature of 36-37°C with an exposure time of each procedure 15 minutes of 8 procedures for the course, through the day; photomicroscopy of 8 procedures for the course, after a day medication, including acceptance selective competitive blocker postsynaptic alpha-adrenergic receptors of artesina (international name: doxazosin (Doxazosin) in a daily dose of 2 mg, which was conducted daily for 10 days.

As a source of EHF-radiation used installation "Yav-1 with a wavelength of 7.1 mm at a power flux density of at least 10 MW/sq cm Aperture of a horn antenna is 2.5 square, see Horn was delivered to the skin in the crotch area and the lumbosacral area of the spine. Maximum of maintaining a continuous radiation is no more than 20 minutes, in the course of treatment 10 treatments.

The method can be illustrated by the following examples:

1. Patient B.p.In., 58 years old, was treated in Zheleznovodsk clinic fsbi PHYIC the FMBA of Russia with 29.10.2011 on 18.11.2011, I. B. No. 1958. Diagnosis: Benign prostatic hyperplasia. Chronic abacterial prostatitis in remission.

Before the treatment complained of recurrent pain in the lower abdomen, perineum, heart, difficulty urinating at night, up to 3-4 times), increasing supercooling, is quickly fatigue, weakness, reduced efficiency, irritability. Sick for 5 years. Repeatedly conducted outpatient treatment, mainly herbal medicine. Upon admission to the hospital objectively: General condition is satisfactory, satisfactory power, emotionally labile, prostate palpation of enlarged, painful. During the examination complete blood count within normal limits; clinical analysis of urine without pathological changes, the level prostatespecific antigen (PSA) of 2.3 ng/ml, residual urine volume of 35 ml, the sum score of IPSS - 14, Qmax, ml/s-7,8, frequency of urination per day - 9 (night 3). Secret of the prostate is a small amount of lecithin grains increased numbers of leukocytes. The volume of the prostate by ultrasound - 42 cubic cm of leukocytes. The volume of the prostate by ultrasound-42 cubic cm

Treatment: on the background of gently-training mode locomotor activity, feeding on diet No. 6 assigned: EHF-therapy, internal reception to the carbon dioxide-bicarbonate-sulfate sodium-calcium water of low salinity - 3,6-3,7 g/l, in the amount of 280-300 ml, three times a day for 40-45 minutes prior to a meal, balneological treatment: bath with the similar mineral water, the temperature of 36-37°C with an exposure time of each procedure 15 minutes of 8 procedures for the course, through the day; photomicroscopy of 8 procedures for the course, through the day; medicamen the religious treatment, including acceptance of artesina in a daily dose of 2 mg, which was conducted daily for 10 days.

Treatment endured well. Improved overall health, disappeared irritability due to improve nighttime sleep, decreased symptoms of lower urinary tract, in particular the symptom of nocturia, decreased fatigue, which greatly affected the quality of life. Pain prostate palpation decreased significantly, parenchyma became more elastic. Secret of the prostate, the number of leukocytes decreased from 15-18 8-10 in the field of view (p/C) the amount of the enzyme lecithin increased from minor to large quantity, level prostatespecific antigen (PSA) decreased from 2.3 ng/ml to 2.0 ng/ml, residual urine volume decreased from 35 ml to 28 ml, the sum score of IPSS decreased to -9, Qmax increased from -7,8 ml/s to 13.4 ml/s, frequency of urination per day decreased from 9 (night 3) to 6 (night 1). Secret of the prostate has increased the amount of lecithin granules, decreased the number of leukocytes. Prostate volume by ultrasonography decreased to 38 cubic cm

Thus, as a result of the treatment has a positive dynamics of both subjective symptoms and functional data and laboratory studies demonstrating the improvement of the clinical status of the adaptation processes and the quality of the VA life in General.

2. Patient A. B. M., 62 years of age, was treated in Zheleznovodsk clinic fsbi PHYIC the FMBA of Russia with 27.05.2011 on 16.06.2011, I. B. No. 884.

Diagnosis: Benign prostatic hyperplasia. Chronic abacterial prostatitis in remission.

Before the treatment complained of recurrent pain in the perineum, heart, difficulty urinating (night 4-5 times), which causes fatigue, weakness, decreased performance, irritability. Sick for 7-8 years. Repeatedly conducted outpatient treatment at the place of residence, without much effect. Upon admission to the hospital objectively: General condition is satisfactory, satisfactory power, emotionally labile, prostate palpation of enlarged, painful. During the examination complete blood count within normal limits; clinical analysis of urine without pathological changes, the level prostatespecific antigen(PSA) 2.7 ng/ml, the volume of residual urine - 38 ml, the sum score of IPSS - 15, Qmax, ml/s to 7.2, frequency of urination per day - 12 (night-4-5). Secret of the prostate is a small amount of lecithin grains increased numbers of leukocytes. The volume of the prostate by ultrasound-39 cubic cm

Treatment: on the background of gentle-training mode locomotor activity, feeding on diet No. 6 assigned: EHF-therapy, I heard the third receiving carbon dioxide-bicarbonate-sulfate sodium-calcium water of low salinity - 3,6-3,7 g/l, in the amount of 280-300 ml, three times a day for 40-45 minutes prior to a meal, balneological treatment: bath with the similar mineral water, the temperature of 36-37°C with an exposure time of each procedure 15 minutes of 8 procedures for the course, through the day; photomicroscopy of 8 procedures for the course, through the day; medication: artesyn in a daily dose of 2 mg daily for 10 days.

Treatment endured well. Improved overall health, the activity appeared through better night's sleep, decreased SNPS, in particular a symptom of nocturia, decreased fatigue, which significantly improved the quality of life. Pain prostate palpation decreased significantly, parenchyma became more elastic. Secret of the prostate, the number of leukocytes decreased from 15-18 8-10 in the field of view (p/C) the amount of the enzyme lecithin increased from minor to large quantity, level prostatespecific antigen (PSA) decreased from 2.7 ng/ml to 2.4 ng/ml, residual urine volume decreased from 38 ml to 25 ml, the sum score of IPSS decreased to -8, Qmax increased from-7.2 ml/s to 12.3 ml/s, frequency of urination per day decreased from 12 (night 4) to 8 (night 1). Secret of the prostate has increased the amount of lecithin granules, decreased the number of leukocytes. Prostate volume by ultrasonography decreased to 35 cubic, see the result of the treatment was the tsya positive dynamics as subjective symptoms, and functional data and laboratory studies, which indicates the improvement of the clinical status of the adaptation processes and the quality of life in General.

3. Patient F. N. And., 68 years of age, was treated in Zheleznovodsk clinic FGI "Pyatigorsk Institute of balneology FMBA of Russia" 06.04.2011 on 26.06.2011, I. B. No. 552.

Diagnosis: Benign prostatic hyperplasia. Chronic abacterial prostatitis in remission.

Before the treatment complained of intermittent discomfort in the crotch area, cresce, heart, difficulty urinating at night, up to 3-4 times), feeling of incomplete emptying of the bladder, fatigue, General weakness, decreased performance, irritability. Sick for 10 years. Several times was conducted outpatient treatment at the place of residence, without much improvement. Upon admission to the hospital objectively: General condition is satisfactory, satisfactory power, emotionally labile, prostate palpation of enlarged, painful. During the examination complete blood count is within normal limits; clinical analysis of urine without pathological changes, the level prostatespecific antigen (PSA) was 3.0 ng/ml, residual urine volume of 45 ml, the sum score of IPSS - 16, Qmax, ml/s-6,4, frequency of urination per day - 10 (overnight is n-4-5). Secret of the prostate sum score of IPSS - 15, Qmax, ml/s and 7.5, frequency of urination per day-12 (night-4-5). Secret of the prostate is a small amount of lecithin granules, increased numbers of leukocytes. The volume of the prostate by ultrasound - 42 cubic cm

Treatment: on the background of gently-training mode locomotor activity, feeding on diet No. 6 assigned: EHF-therapy, internal reception to the carbon dioxide-bicarbonate-sulfate sodium-calcium water of low salinity - 3,6-3,7 g/l, in the amount of 280-300 ml, three times a day for 40-45 minutes prior to a meal, balneological treatment: bath with the similar mineral water, the temperature of 36-37°C with an exposure time of each procedure 15 minutes of 8 procedures for the course, through the day; photomicroscopy of 8 procedures for the course, through the day; medication: artesyn in a daily dose of 2 mg daily for 10 days.

Treatment endured well. Improved overall health, decreased symptoms of lower urinary tract by reducing the symptom of nocturia, almost normal night's sleep, which significantly improved the quality of life. Pain prostate palpation decreased significantly, parenchyma became more elastic. Secret of the prostate, the number of leukocytes decreased from 20-25 7-10 in the field of view (p/C) the amount of the enzyme lecithin increased from negligible to a large number of the quality level prostatespecific antigen (PSA) decreased from 3.0 ng/ml to 2.6 ng/ml, residual urine volume decreased from 45 ml to 30 ml, the sum score of IPSS decreased to -9, Qmax increased c -7,5 ml/s to 12.2 ml/s, frequency of urination per day decreased from 10 (night 4) to 8 (night 1). Secret of the prostate has increased the amount of lecithin granules, decreased the number of leukocytes. Prostate volume by ultrasonography decreased to 36 cubic, see the result of the treatment has a positive dynamics of both subjective symptoms and functional data and laboratory studies, which indicates the improvement of the clinical condition and quality of life in General.

The proposed method was applied in the conditions of Zheleznovodsk clinic fsbi PHYIC the FMBA of Russia on two groups of patients - main (30 people) and the comparison group (30 people)treated by the new method and the prototype, respectively. The age of patients from 45 to 70 years.

All patients complained of General weakness, fatigue, disturbed night sleep. When applying for a Spa treatment period of adaptation were more difficult. These complaints patients was associated with symptoms of lower urinary tract with the dominant symptom of nocturia that significantly worsened the quality of life. On a scale IPSS (international system total the assessment of symptoms in diseases of the prostate) all the patients showed a moderate degree of disturbance of urination, the index measuring the quality of life was noted as unsatisfactory.

To determine the effectiveness of medication in combination with therapy patients were divided into 2 groups (30 people each), of which one (the control) received EHF-therapy, mineral water for indoor and outdoor use, photomicroscopy, the other (main) advanced medical treatment for 10 days (artesyn 2 mg/day). Distribution of patients according to clinical characteristics in the main and control groups were representative.

Comparing the estimate of the treatment in the main and control groups, it was possible to note that end-of-course Spa therapy has been a significant decrease in symptoms of lower urinary tract, in particular the symptom nocturia (from 4-5 to 1-2 urination at night), improved IPSS (15-16 7-8 points), also improved Qmax (from 7 to 15 ml/s). In addition, improved quality of life for patients.

When palindrome analysis identified the most effective treatment in patients of group II, treated along with balneotherapy medication.

Dynamics of key clinical indicators under the influence of complex Spa therapy in these patients depending on the applied medical complex from the Agen in tables 2 and 3.

When comparing the results of Spa treatment in two groups of patients revealed the advantage of the complex with drug treatment. In this case, a positive therapeutic effect was observed in a more significant amount.

The proposed method enables restorative treatment of benign prostatic hyperplasia, complicated by chronic prostatitis dominant symptom of nocturia with EHF-therapy, mineral water, mineral baths, photomicroscopy and medication (selective competitive blocker postsynaptic alpha-adrenergic receptor-artesina). This is manifested by a significant improvement in the condition of patients in clinical examination, and according to indicators IPSS, Qmax, reducing symptoms of the lower urinary tract with the dominant symptom of nocturia from 4-5 to 1-2 urination at night and improve the quality of life of patients.

Method of treatment of benign prostatic hyperplasia, complicated by chronic prostatitis dominant symptom of nocturia, including EHF-therapy, wherein the patient spend additional complex Spa treatment: internal reception to the carbon dioxide-bicarbonate-Sul is Fatou sodium-calcium water of low salinity - 3,6-3,7 g/l, in the amount of 280-300 ml, three times a day for 40-45 minutes prior to a meal, balneological treatment: bath with the similar mineral water, the temperature of 36-37°C with an exposure time of each procedure 15 minutes of 8 procedures for the course, through the day; photomicroscopy of 8 procedures for the course, through the day; and daily prescribed medication by artesina 2 mg/day for 10 days.



 

Same patents:

FIELD: medicine.

SUBSTANCE: present group of inventions refers to medicine, namely to urology, and concerns treating prostatic diseases. That is ensured by administering a therapeutic agent containing an activated-potentiated form of prostate-specific antigen antibody and using the activated-potentiated form of endothelial NO-synthase antibodies as an additional exalting agent.

EFFECT: administering this combined therapeutic agent provides the effective treatment of the prostatic diseases by the synergetic effect of the ingredients consisting in intensifying the antiproliferative, anti-inflammatory effects and improving the functional state of the prostate.

10 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to an agent for treating benign prostatic hyperplasia. The antiproliferative agent for treating benign prostatic hyperplasia which contains red deer's antler lipids prepared by extraction of the red deer's antlers in a mixture of the solvents ethanol: ethyl acetate: water in the specific environment.

EFFECT: agent is effective for treating benign prostatic hyperplasia.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to methods of treating diseases of various aetiologies and injuries of various visceras. Electropunctural pre-examination aims at determining the patient's overall potential and the potential in a point on the body surface at a minimal distance from the viscera to be treated, or in its immediate projection tender zones. A stem cell growth area is stimulated by placing a bee within the sternum. Then, an irritation centre is created using vacuum- or hirudotherapy in a point on the body surface at a minimal distance from the above viscera or in its immediate projection tender zones. The irritation centre is created to be intensive and short-term at the level of the potential in the point below the overall potential, or to be weak and long-term at the level of the potential in a point above the overall potential.

EFFECT: method provides the effective local therapeutic effect on the involved visceral tissues ensured by a combination of the used components of the effect.

2 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to urology, and can be used for treatment of benign hyperplasia of prostate gland. For this purpose dynamic examination of prostate gland is carried out before drug therapy and 3, 6 and 9 months after that. Dynamic examination includes transrectal ultrasound examination (TRUSE) with Dopplerography and sonoelastography (SEG) of prostate gland. Comparison of prostate size values, hyperplasia size, blood flow in capsular and parauretral arteries, blood flow in adenomatous nodes and density of transitory zones of prostate is carried out in SEG. If values of examined parameters by TRUSE data decrease by 15% and more, each parameter is given 1 point. If density of transitory zones of prostate in sonoelastography is higher than 35 KPa, 1 point is given too. As a result if the sum is not less than 4 points, conservative therapy is stopped. If the sum of points is less than 4 points, therapy is continued. Examination is repeated after next 3 months.

EFFECT: method ensures reduction of terms of drug treatment and increase of treatment quality due to possibility of determining indications for complete or partial cancellation of drug treatment within 3-6 months.

1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is using at least one protease for producing a drug preparation for treating and/or preventing benign prostatic hypertrophy/hyperplasia wherein the drug preparation is acceptable for the oral administration with at least one protease being specified in a group consisting of plant and microorganism proteases, and with at least one protease being administered in the amount of 1 to 100 mg/kg of body weight, and a respective pharmaceutical preparation.

EFFECT: what is shown is reducing high vascular endothelial growth factor in patient's blood under the action of a mixture of enzymes that makes it possible to inhibit angiogenic growth factors (VEGF), thereby leading to lower vascularisation, and reducing benign prostatic hypertrophy/hyperplasia, with the enzymatic therapy under the present invention having no effect on the normal VEGF level.

13 cl, 7 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely urology, and may be used for treating suppurative septic complications of prostate adenoma. For this purpose, with underlying administering antibiotics, ozonised saline solution in the concentration of 3 to 6 mg/l in the amount of 200 to 400 ml is additionally intravenously administered; the therapeutic course is 3-5 injections depending on the patient's state. Besides, ozonised saline solution in the concentration of 5 to 8 mg/l is injected into the bladder in the preoperative preparation period, and from the second postoperative day, saline solution is introduced drop-by-drop in the amount of 400.0 ml daily five times with a two-way flushing system.

EFFECT: method enables reducing the risk of urosepsis, eliminating intoxication and accelerating postoperative wound healing of a BPH bed by anti-inflammatory, detoxification, analgesic action, improved blood rheology and microcirculation, increased local immunity with activated regenerative and reparative processes.

2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (1), in which Ar is a group of formula (Ar-1) or (Ar-2), in which R1 is a halogen, R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, alkyl or alkenyl, X is a nitrogen atom or CH, R5 and R6 are each hydrogen and h equals 1; 1 equals 1 or 2; m equals 1 or 2; n equals 0, 1 or 2; o equals an integer from 0 to 3, under the condition that n and o are equal to 0 at the same time. Values of group A are as given in claim 1 of the invention. Described also is a pharmaceutical composition having agonistic activity with respect to 7 serotonin (5-HT4-receptors), which contains a compound of formula (1) and an agent which stimulates enterokinesis or improves functioning of the alimentary canal, which contains a compound of formula (1) as an active ingredient.

EFFECT: novel compounds are obtained and described, which have strong affinity towards 4 serotonin receptors, which are useful as an agent which stimulates enterokinesis or an agent which improves functioning of the alimentary canal.

28 cl, 233 ex, 29 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to urology, and can be used for treatment of chronic abacterial prostatitis in men, which is not connected with dysfunction of urethral sphincter. For this purpose, efficient amount of fispemiphene is introduced to patient who needs it. Introduction of fispemiphene is performed in amount in the range from 0.1 to approximately 100 mg/kg of body weight.

EFFECT: invention ensures efficient treatment of abacterial prostatitis at the early stage of disease where only histological changes of prostate gland are present without presence of urethral sphincter dysfunction, with drug fispemiphene, which demonstrates antagonistic activity to estrogen receptors in particular with respect to prostate tissue.

2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutical industry, in particular to composition, which contains epigallocatechine-3-gallate as active component and target additive. Pharmaceutical composition for peroral introduction, which contains epigallocatechine-3-gallate and block-copolymer of oxyethylene and oxypropylene, in which content of hydrophobic block constitutes not less than 50 wt %, and molecular weight of hydrophilic block constitutes 2250 Dalton and not more, with specified weight ratio of epigallocatechine-3-gallate and block copolymer 1:1-10:1. Application of upper described pharmaceutical composition for treatment of atopic dermatitis, Crohn's disease, adenomyosis, and hyperplastic diseases of prostate.

EFFECT: composition has increased bioavailability in peroral application, improves absorption of active compound epigallocatechine-3-gallate in blood flow.

6 cl, 2 dwg, 4 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacy, namely technology of preparation of rectal suppositories. The suppositories with solid licorice extract consist of solid licorice extract 0.75 g on a hydrophilic base, polyethylene glycol 6000 1.25 g and polyethylene glycol polystear 0.25 g.

EFFECT: making the preparations exhibiting anti-inflammatory action, and also a positive effect on the hormonal status and the copulative function.

7 tbl

FIELD: medicine.

SUBSTANCE: main active factor of a photophoresis apparatus is an effect of a linear spectrum of a number of chemical elements emitted by a cathode so that gross power makes approximately 1 mW. The apparatus comprises an anode and a hollow cathode enclosed in a hermetic cylinder filled with inert gas and provided with a glass output window; the cathode comprises chemical powders aggregating a multiple-element linear emission spectrum of the cathode with evident spectral lines characteristic for the chemicals placed on the cathode: calcium, magnesium, potassium, sodium, manganese, copper, zinc, iron, selenium, silicon, platinum.

EFFECT: apparatus enables optimising the skin microelement balance and providing its safety in cosmetology ensured by a low power level.

3 cl, 2 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: treating locally advanced unresectable pancreatic cancer is ensured by arterial chemoinfusion with the use of the preparations Gemzar 1,000 mg/m2/30 min and Eloxatin 50 mg/m2/120. The infusion is cyclic at least 2 months apart. The 1st to 4th arterial chemoinfusion cycles precede a radiation therapy, and no later than within 3 months in the same regimens - after the radiation therapy to disease progression. The radiation therapy is conformal and performed not earlier than 1 month after the first 1st-4th arterial chemoinfusion cycles at a single radiation dose of 3 Gy 5 times a week to a total radiation dose of 51 Gy.

EFFECT: effective treatment with no haematological and general toxic complications, and satisfactory patient's quality of life throughout the therapeutic course.

2 ex

FIELD: medicine.

SUBSTANCE: chemotherapy is conducted with using the preparations Gemzar 1000 mg/m2/30 min and Eloxatin 50 mg/m2/120 min. The chemopreparations are administered by arterial infusion cycles at least every 2 months. 1 to 4 arterial chemoinfusion cycles precede a radiation therapy, and no later than within 2 months in the same regimens - after the radiation therapy to disease progression. The radiation therapy is performed not earlier than 1 month after the first 1-4 arterial chemoinfusion cycles at a single radiation dose of 3 Gy 5 times a week to a total radiation dose of 51 Gy.

EFFECT: effective treatment with no haematological complications, reduced general toxicity and patient's satisfactory quality of life for the whole therapeutic course.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, rehabilitation, physiotherapy, namely to - electrical therapy. A body is exposed to an electron flow generated by at least one electrode parameters of which are specified within: current intensity up to 50 mA and current frequency from zero to 1.7×1015 Hz. At least one ground electrode with constant or variable resistance specified within 1×10-2 Ohm to 2×109 Ohm included, and at a frequency from zero to 1.7×1015 Hz is additionally applied on the body. The body can be additionally exposed to electromagnetic waves at a frequency specified from zero to 1.7×1015 Hz. Before the electrodes are applied on the body, an application point of at least one electrode is coated with a drug or a biologically active substance. At least one negative electrode is switched at least once, so the electrode becomes ground, and at least one ground electrode is switched and becomes the negative electrode.

EFFECT: method provides neutralising excessive free radicals in the body, improves metabolism and blood flow, with additionally increased speed and evenness of electrons in the body by activating electron routes by the ground electrode.

4 cl, 1 dwg, 9 ex

FIELD: medicine.

SUBSTANCE: apparatus for remote neutron therapy is intended for treating of radioresistant forms of oncologic diseases. Its construction includes a base, providing ±180° rotation of a balanced console with a neutron head. The neutron head consists of a neutron generator, a radiation protection with an in-build in it neutron channel. In the generator as a source of neutrons a nuclear reaction 3T(d,n)4He is applied. The neutron head is placed on the balanced console with a mechanism of its longitudinal travel. Different sizes of neutron fields on the patient's body are formed by means of wedges. To measure the distance from the source of neutrons to the patient there is a laser or a microwave ruler and a video camera with LEDs for visualising superposition of the marked contour of irradiation on the patient's body with an image of the output opening of the neutron channel. To reduce an impact of directed radioactivity on the attendant personnel the cooled substrate of the target and walls of the neutron channel are made from selected materials, also introduced is a protective box for placement of the neutron head in it by a robotised device during the patient's positioning.

EFFECT: invention makes it possible to reduce exposure of the personnel to radiation.

9 cl, 2 dwg

FIELD: medicine.

SUBSTANCE: invention relates to physiotherapeutic devices. Device contains case with optically transparent surface, magnetic conductor and radiator. In case located are: light emitter, made in form of powerful three-colour RBG LED, and electromagnetic emitter, made in form of coil, connected to power unit via control means. Magnetic conductor is made in form of stepped cylinder, and radiator is made in form of thick-walled cup from heat-conducting material. Radiator is installed in cylinder of magnetic conductor of larger diameter, connected with internal surface of case, cylinder of magnetic conductor of smaller diameter is connected with internal surface of coil, LED is installed on radiator.

EFFECT: application of invention ensures improvement of treatment quality due to increase of depth of magnetic field impact and increase of light radiation power.

5 cl, 1 dwg

FIELD: medicine.

SUBSTANCE: 30-60 minutes after the following fraction of radical irradiation on the 1st, 3rd and 5th day of each week for the whole period of irradiation, the preparation Molixan® 60 mg (2 ml) is introduced intramuscularly to the patient.

EFFECT: higher efficacy and safety of the chemotherapy ensured by relieving the manifestations of oral mucositis.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely therapeutic dentistry and may be used for treating destructive forms of chronic periodontitis. That is ensured by administering a therapeutic preparation into a root canal. A sonic phoresis of the therapeutic preparation Beresh plus drops is preceded by coating the skin surrounding a causative tooth with a therapeutic mixture containing the preparation Beresh plus drops, 10% calcium gluconate and Vaseline oil. Thereafter, an emitter is used to process the area. The sonic phoresis is followed by a root canal obturation with calcium hydroxide. That is combined with administering ascorbic acid in a daily dose of 50-100 mg and the preparation Beresh plus drops 1 drop per 2 kg of body weight a day orally. The therapeutic course is 5-8 procedures.

EFFECT: invention enables arresting the inflammatory process in the aggressive lesion, reducing the number of complications and aggravations ensured by accelerating the repair processes in the apical aggressive lesion.

2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to - physiotherapy. Pressure pulse frequency is pre-measured. Patient's acoustic and/or visual organs are exposed to sound and/or light pulses at pre-set frequency. For the first 100-300 seconds of the exposure, the sound and/or light pulses are supplied at constant conditions of frequency corresponding to the pre-measured pulse frequency; then for 900-1100 seconds of the exposure, the pulses are supplied at variable conditions with gradually varying frequency and rhythm of the sound and/or light pulses.

EFFECT: method enables the non-invasive effect on heart rate and rhythm.

5 ex, 5 tbl, 11 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology and concerns treating locally advanced vaginal cancer. For this purpose, the therapy is staged. The first stage involves the chemotherapeutic course that provides administering cisplatin 100 mg/m and doxorubicine 30 mg/m2 intravenously drop-by-drop; the gamma-ray teletherapy covering a primary centre in a dose of 20 Gy is followed by two fractions 2.5 Gy of the intracavitary Co60 therapy every 5 hours twice a week; in the middle of the 5-hour period, platidiam 5 mg dissolved in saline solution 1.0 ml is introduced into surface layers of the tumour which is exposed to ultrasound of frequency 880 kHz and intensity 0.4 Wt/cm2 through the licensed dimexide gel tissue for 5 minutes; the therapy requires the gamma-ray teletherapy covering the lymphatic nodes alternated with 10-11 sessions of the intracavitary Co60 therapy in total to reach a total dose of the primary centre exposure of 70-75 Gy, of the lymphatic nodes exposure of 40 Gy.

EFFECT: specified integrated therapy provides the effective treatment and prevention of the recurrences also ensured by using the chemotherapy combined with the ultrasonic exposure that promotes the deeper chemopreparation penetration into tumour tissues.

1 ex

FIELD: medicine.

SUBSTANCE: what is presented is using magnesium salt of comenic acid as a preventive and therapeutic agent in an amount of 2 mg per 1 kg of body weight for 3 days orally on an empty stomach once a day.

EFFECT: there are shown antioxidant and neuroprotective activities of magnesium comenate, as well as its stimulant action on the growth processed of spinal ganglia exceeding that of the action of comenic acid.

7 tbl

Up!